[HTML][HTML] The dynamics of more-than-human care in depot buprenorphine treatment: A new materialist analysis of Australian patients' experiences
Background Long-acting injectable depot buprenorphine has become an important
treatment option for the management of opioid dependence. However, little is known about …
treatment option for the management of opioid dependence. However, little is known about …
Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a …
B Johnson, B Monwell, AJ Capusan - Harm Reduction Journal, 2024 - Springer
Background Long-acting injectable depot buprenorphine may increase access to opioid
agonist treatment (OAT) for patients with opioid use disorder in different treatment phases …
agonist treatment (OAT) for patients with opioid use disorder in different treatment phases …
Healthcare staff's perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study
J Nordgren, B Monwell, B Johnson… - Addiction science & …, 2024 - Springer
Background Long-acting injectable buprenorphine (LAIB) formulations are a novel treatment
approach in opioid agonist treatment (OAT), which provide patients with a steady dose …
approach in opioid agonist treatment (OAT), which provide patients with a steady dose …
Patients' Perspectives on Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder
Objectives Buprenorphine and other medications for opioid use disorder (OUD) are
recommended as standard of care in the treatment of OUD and are associated with positive …
recommended as standard of care in the treatment of OUD and are associated with positive …
Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA
HA Blair - Drugs & Therapy Perspectives, 2024 - Springer
Buprenorphine extended-release (ER) injection for subcutaneous use (Brixadi®; CAM2038;
hereafter referred to as buprenorphine ER) is a useful addition to the treatment options for …
hereafter referred to as buprenorphine ER) is a useful addition to the treatment options for …
'Matters-of-concern'associated with discontinuation of long-acting injectable buprenorphine: Findings from a longitudinal qualitative study
Background Discontinuation of medications such as methadone and buprenorphine
amongst patients receiving opioid agonist treatment (OAT) is an international phenomenon …
amongst patients receiving opioid agonist treatment (OAT) is an international phenomenon …
[HTML][HTML] Trends in use of medicines for opioid agonist treatment in Australia, 2013–2022
Background There are limited longitudinal data on national patterns of opioid agonist
treatment (OAT). This study describes 10-year trends in the sales of OAT medicines in …
treatment (OAT). This study describes 10-year trends in the sales of OAT medicines in …
Att vara en” bra” patient: Patienters upplevelser av avvänjande opioidbehandling
LA Holl, L Bremsjö - 2023 - diva-portal.org
Opioider används inom hälso-och sjukvården för behandling av olika smärttillstånd. Vid
långvarig behandling med opioider finns risk för beroendeutveckling. Tolerans, som är en …
långvarig behandling med opioider finns risk för beroendeutveckling. Tolerans, som är en …
[PDF][PDF] Kendal Chidwick, Natasa Gisev, Louisa Degenhardt
M Farrell, C Bharat - ndarc.med.unsw.edu.au
Opioid agonist treatment (OAT) is one of the main treatments for people with opioid
dependence1. Involving long-term pharmacotherapy with an opioid agonist or partial …
dependence1. Involving long-term pharmacotherapy with an opioid agonist or partial …